New drug shows promise in killing cancer cells with genetic vulnerability

Imagine the body’s cells are well-behaved students in the classroom. The “teachers” are tumor suppressor genes, and they make sure cells follow the rules. But when tumor suppressor genes are away, cells may go astray.

P-BCMA-ALLO1 by F. Hoffmann-La Roche for Refractory Multiple Myeloma: Likelihood of Approval – Pharmaceutical Technology

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

October 26, 2023

Cardiovascular Protection Tracks With Wine Intake, Now Provable With Urinary Marker

Drinking 12-35 glasses of wine a month was tied to a lower risk of combined heart failure, myocardial infarction, stroke, and cardiovascular death over a

December 19, 2024

CD70 CAR-T by UTC Therapeutics for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

August 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.